Silvan Tuerkcan
Stock Analyst at JMP Securities
(1.26)
# 3,249
Out of 4,810 analysts
156
Total ratings
31.33%
Success rate
-15.87%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTC Benitec Biopharma | Maintains: Market Outperform | $18 → $20 | $13.68 | +46.20% | 11 | Apr 10, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Market Outperform | $17 | $2.15 | +690.70% | 5 | Mar 26, 2025 | |
| ELEV Elevation Oncology | Downgrades: Market Perform | $7 | $0.31 | +2,132.85% | 7 | Mar 21, 2025 | |
| GBIO Generation Bio Co. | Reiterates: Market Perform | n/a | $0.37 | - | 8 | Mar 14, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $2.70 | +455.56% | 2 | Mar 7, 2025 | |
| PRME Prime Medicine | Reiterates: Market Outperform | $10 | $1.32 | +657.58% | 2 | Mar 4, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $38.95 | +120.80% | 14 | Feb 13, 2025 | |
| EXEL Exelixis | Maintains: Market Outperform | $41 | $36.54 | +12.21% | 20 | Jan 27, 2025 | |
| JSPR Jasper Therapeutics | Reiterates: Market Outperform | $70 | $4.23 | +1,554.85% | 5 | Jan 10, 2025 | |
| CNTX Context Therapeutics | Initiates: Market Outperform | $4 | $0.84 | +374.50% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.00 | +350.00% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $2.76 | +660.87% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $12 | $0.70 | +1,614.29% | 11 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $2.40 | +733.33% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $1.27 | +293.70% | 11 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.26 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.46 | +310.96% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $251.10 | +11.51% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.01 | +63.49% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.36 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $6.95 | -56.80% | 3 | May 10, 2022 |
Benitec Biopharma
Apr 10, 2025
Maintains: Market Outperform
Price Target: $18 → $20
Current: $13.68
Upside: +46.20%
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.15
Upside: +690.70%
Elevation Oncology
Mar 21, 2025
Downgrades: Market Perform
Price Target: $7
Current: $0.31
Upside: +2,132.85%
Generation Bio Co.
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.37
Upside: -
Solid Biosciences
Mar 7, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $2.70
Upside: +455.56%
Prime Medicine
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $1.32
Upside: +657.58%
CRISPR Therapeutics AG
Feb 13, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $38.95
Upside: +120.80%
Exelixis
Jan 27, 2025
Maintains: Market Outperform
Price Target: $41
Current: $36.54
Upside: +12.21%
Jasper Therapeutics
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $4.23
Upside: +1,554.85%
Context Therapeutics
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.84
Upside: +374.50%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $18
Current: $4.00
Upside: +350.00%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $2.76
Upside: +660.87%
Dec 10, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.70
Upside: +1,614.29%
Dec 4, 2024
Reiterates: Market Outperform
Price Target: $20
Current: $2.40
Upside: +733.33%
Nov 12, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.27
Upside: +293.70%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.26
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.46
Upside: +310.96%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $251.10
Upside: +11.51%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.01
Upside: +63.49%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.36
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $6.95
Upside: -56.80%